Meningococcal Disease: Clinical Trials

23 trials for Meningococcal Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 completed. 23 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 323Completed 23
Phase 23Completed 3

Follow Meningococcal Disease: new trials by email Literature Review of Meningococcal Disease trials Research Report on Meningococcal Disease

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.
Bexsero®, Routine vaccines - Meningococcal Disease, Infections, Meningococcal
Phase 3CompletedGlaxoSmithKline2252014-09-112020-08-25
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
rMenB+OMV - Meningococcal Disease
Phase 3CompletedNovartis2392014-05-012017-02-15
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.
Meningococcal B Recombinant vaccine rMenB+OMV NZ, Placebo, Meningococcal ACWY-CRM conjugate vaccine - Meningococcal Disease
Phase 3CompletedNovartis Vaccines2642013-11-012015-10-30
A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults
Recombinant meningococcal B + OMV NZ - Meningococcal Disease, Meningococcal Meningitis
Phase 3CompletedNovartis Vaccines182013-05-012015-03-27
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, 2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine - Meningococcal Disease, Meningococcal Meningitis
Phase 3CompletedNovartis Vaccines8052012-11-012015-01-13
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia
MenACWY-CRM - Meningococcal Disease
Phase 3CompletedNovartis Vaccines1982012-11-012023-04-28
Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.
MenACWY-CRM - Meningococcal Disease, Infections, Meningococcal
Phase 3CompletedGlaxoSmithKline7152012-10-072019-06-14
Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed - Meningitis, Meningococcal Disease
Phase 3CompletedSanofi Pasteur, a Sanofi Company3002012-07-012013-12-03
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis
Phase 3CompletedNovartis5522011-11-012014-03-11
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
MenACWY-CRM, Combined inactivated hepatitis A & recombinant hepatitis B, Recombinant hepatitis B vaccine - Meningococcal Disease, Meningococcal Meningitis
Phase 3CompletedNovartis Vaccines2522011-10-012017-06-08
Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years
Serogroup B meningococcal vaccine - Meningococcal Disease, Meningococcal Meningitis
Phase 3CompletedNovartis3442011-08-012015-02-20
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
MenACWY-CRM - Meningococcal Disease
Phase 3CompletedNovartis Vaccines2052011-05-012018-06-18
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
rMenB + OMV NZ vaccine, Meningococcal C oligosaccharide conjugated vaccine, Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. - Meningococcal Disease, Meningococcal Meningitis
Phase 3CompletedNovartis Vaccines14092011-04-012016-05-09
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
Novartis MenACWY-CRM, Saline Placebo - Meningococcal Disease, Meningococcal Meningitis
Phase 3CompletedNovartis Vaccines4502010-12-012012-10-16
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
MenACWY-CRM, Routine Vaccines - Meningococcal Disease, Meningococcal Meningitis
Phase 3CompletedNovartis Vaccines7512010-10-012018-10-09
Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10
No Vaccine, rMenB+OMV-NZ - Meningococcal Disease, Meningococcal Meningitis
Phase 2 / Phase 3CompletedNovartis Vaccines8172010-08-012018-06-15
One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age
rMenB+OMV NZ - Meningococcal Disease
Phase 3CompletedNovartis Vaccines5082010-06-012015-04-10
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
MenACWY-CRM, DTaP-IPV/Hib, HBV - Meningococcal Disease
Phase 3CompletedNovartis Vaccines5292009-11-012014-04-21
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12
rMenB+OMV NZ with routine vaccinations, rMenB+OMV NZ, two doses of rMenB+OMV NZ - Meningococcal Disease, Meningococcal Meningitis
Phase 2 / Phase 3CompletedNovartis Vaccines15882009-07-012017-08-14
Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
1a - rMenB+OMV NZ and routine vaccines, 1b - rMenB+OMV NZ and routine vaccines, 2a - Routine and rMenB+OMV NZ vaccines - Meningococcal Disease
Phase 3CompletedNovartis Vaccines22492009-02-012015-03-03

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Meningococcal Infections (23)  ·  Meningitis (11)  ·  Meningitis, Meningococcal (11)  ·  Encephalitis, Japanese (1)  ·  Hepatitis A (1)  ·  Hepatitis B (1)  ·  Hereditary Complement Deficiency Diseases (1)  ·  Rabies (1)  ·  Typhoid Fever (1)  ·  Yellow Fever (1)

Broader conditions

Bacterial Infections (23)  ·  Bacterial Infections and Mycoses (23)  ·  Gram-Negative Bacterial Infections (23)  ·  Infections (23)  ·  Neisseriaceae Infections (23)  ·  Nervous System Diseases (18)  ·  Neuroinflammatory Diseases (18)  ·  Central Nervous System Bacterial Infections (11)  ·  Central Nervous System Diseases (11)  ·  Central Nervous System Infections (11)  ·  Meningitis, Bacterial (11)  ·  Meningitis (7)  ·  RNA Virus Infections (2)  ·  Virus Diseases (2)  ·  Arbovirus Infections (1)

Interventions

MenACWY-CRM vaccine (7)  ·  4CMenB vaccine (3)  ·  Hepatitis B Vaccines (2)  ·  Tetanus Toxoid (2)  ·  13-valent pneumococcal vaccine (1)  ·  Engerix-B (1)  ·  Heptavalent Pneumococcal Conjugate Vaccine (1)  ·  Japanese Encephalitis Vaccines (1)  ·  Measles-Mumps-Rubella Vaccine (1)  ·  Meningococcal Vaccines (1)  ·  Rabies Vaccines (1)  ·  Rubella Vaccine (1)  ·  Vi polysaccharide vaccine, typhoid (1)  ·  Yellow Fever Vaccine (1)  ·  adacel (1)

Sponsors

Novartis Vaccines (17)  ·  Novartis (3)  ·  GlaxoSmithKline (2)  ·  Sanofi Pasteur, a Sanofi Company (1)

Countries

Italy (6)  ·  Czechia (5)  ·  Germany (5)  ·  Spain (4)  ·  Canada (3)  ·  South Korea (3)  ·  United Kingdom (3)  ·  United States (3)  ·  Australia (2)  ·  Chile (2)  ·  Finland (2)  ·  Russia (2)  ·  Argentina (1)  ·  Austria (1)  ·  Belgium (1)

Results publications

PMID 33020485, PMID 19895922, PMID 20164251, PMID 22260988, PMID 23324563, PMID 24873986, PMID 25308927, PMID 25483566, PMID 26232542, PMID 26398741, PMID 26479973, PMID 26756390, PMID 26826544, PMID 28318767, PMID 29038320, PMID 29253560, PMID 30068713, PMID 31110098, PMID 31327652, PMID 33325757

NIH funding

2005 (1), 2008 (1), 2009 (1), 2014 (1)